Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model.

Publication Type:

Journal Article


Cancer research, Volume 52, Issue 1, p.89-94 (1992)


Acute Disease, Animals, Antibodies, Monoclonal, Antigens, CD, Antigens, CD45, Antigens, Differentiation, Myelomonocytic, Histocompatibility Antigens, Humans, Iodine Radioisotopes, Leukemia, Myeloid, Male, MICE, Mice, Inbred BALB C, Neoplasm Transplantation, Sialic Acid Binding Ig-like Lectin 3


Acute myeloid leukemia is an attractive disease to treat with radiolabeled antibodies because it is radiosensitive and antibody has ready access to the marrow cavity. In order to evaluate potentially useful radiolabeled antibodies against human acute myeloid leukemia, we have developed a nude mouse xenograft model using the human acute leukemia cell line, HEL. Mice with s.c. xenografts of HEL cells received infusions of radioiodinated anti-CD33 antibody. Examination of the biodistribution of the antibody showed that uptake in the s.c. tumor was maximal [16.9% injected dose (ID)/g at 1 h after infusion] following infusion of 1-10 micrograms of antibody and decreased following infusion of 100 micrograms (6.5% ID/g at 1 h) presumably as a result of saturation of antigen sites. The radiolabel was poorly retained in tumor (4.5-8.2% ID/g at 24 h after infusion). These results were consistent with in vitro studies demonstrating rapid internalization and catabolism of the anti-CD33 antibody. Uptake in tumor could be improved by using either a radiolabel that is retained intracellularly, 111In-DTPA (18.5% ID/g at 24 h), or by targeting a surface antigen that does not internalize upon antibody binding, CD45 (20.5% ID/g at 24 h). These results indicate that this model system will be useful in evaluating the interaction of radiolabeled antibodies with human acute myeloid leukemia cells in an in vivo setting.